The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Petrov A.V.

State Research Institute of Highly Pure Biopreparations, Federal Biomedical Agency, St. Petersburg, Russia

Pavlenko I.A.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Gorelik M.Z.

GBUZ "Primorskoe kraevoe patologoanatomicheskoe biuro", Vladivostok

Gene amplification and coamplification in breast cancer: Frequency and prognosis value

Authors:

Petrov A.V., Pavlenko I.A., Gorelik M.Z.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2013;75(1): 54‑57

Read: 3379 times

Download PDF (RU)
Contact the author
Table of contents

GENE AMPLIFICATION AND COAMPLIFICATION IN BREAST CANCER: FREQUENCY AND PROGNOSIS VALUE
GENE AMPLIFICATION AND COAMPLIFICATION IN BREAST CANCER: FREQUENCY AND PROGNOSIS VALUE

To cite this article:

Petrov AV, Pavlenko IA, Gorelik MZ. Gene amplification and coamplification in breast cancer: Frequency and prognosis value. Russian Journal of Archive of Pathology. 2013;75(1):54‑57. (In Russ.)

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;(2):5-10
The possibilities of predicting and redu­cing the risk of breast cancer in women against the background of the use of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64
Neoadjuvant drug therapy and onco­logical outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(1):5-12
Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant poly­chemotherapy depe­nding on Ki-67 levels. P.A. Herzen Journal of Onco­logy. 2025;(2):13-18
Repeated breast reco­nstruction after previous complications. Piro­gov Russian Journal of Surgery. 2025;(6):51-57
Guidelines for asse­ssing the quality of mammographic images. Russian Journal of Preventive Medi­cine. 2025;(6):21-32
Hema­tological indi­cators of the systemic inflammatory response in the prognosis of lumi­nal HER2-negative breast cancer patients unde­rgoing surgery followed by adju­vant therapy. P.A. Herzen Journal of Onco­logy. 2025;(3):31-38
Hemo­stasis diso­rders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(3):39-44
Inci­dence of regional lymph node meta­stases in patients with early prognostically unfa­vorable mole­cular biological breast cancer. Piro­gov Russian Journal of Surgery. 2025;(7):11-15
Auto­logous fat transplantation into post-lymphadenectomy cavity for prevention of lymphorrhea after total mastectomy. Piro­gov Russian Journal of Surgery. 2025;(7):24-35
Abstract:

Numerical impairments in genes or some genome sites - gene amplifications or deletions - are one of the most frequent genetic mutations occurring in breast cancer. Gene amplifications in breast cancer, their frequency, prognostic value, and the possible role of these disorders in the identification of the subtypes of this heterogeneous disease are considered.

Keywords:

gene amplification
breast cancer
FISH analysis

Authors:

Petrov A.V.

State Research Institute of Highly Pure Biopreparations, Federal Biomedical Agency, St. Petersburg, Russia

Pavlenko I.A.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Gorelik M.Z.

GBUZ "Primorskoe kraevoe patologoanatomicheskoe biuro", Vladivostok

Close metadata

References:

  1. Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. J. Pathol. 2011; 223: 307-17.
  2. Kenemans P., Verstraeten R.A., Verheijen R.H.M. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas. 2004; 49: 34-43.
  3. Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., van de Vijver M.J., eds. WHO Classification of tumours of the breast. IARC: Lyon; 2012.
  4. Jönsson G., Staaf J., Vallon-Christersson J., Ringnér M., Holm K., Hegardt C. et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010; 12: R42.
  5. Natrajan R., Weigelt B., Mackay A., Geyer F.C., Grigoriadis A., Tan D.S. et al. An integrative genomic and trancriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat. 2010; 121: 575-89.
  6. Rakha E.A., Reis-Filho J.S., Baehner F., Dabbs D.J., Decker T., Eusebi V. et al. Breast cancer prognostic classification in the molecular era: the role of hostological grade. Breast Cancer Res. 2010; 12: 207.
  7. Möllerström E., Delle U., Danielsson A., Parris T., Olsson B., Karlsoon P. et al. High-resolution genomic profiling to predict 10-year overall survival in mode-negative breast cancer. Cancer Genet. Cytogenet. 2010; 198: 79-89.
  8. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A. et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-52.
  9. Ross J.S. Multigene classifiers, prognostic factors. And predictors of breast cancer clinical outcome. Adv. Anat. Pathol. 2009; 16: 204-15.
  10. Bizari L., Silva A.E., Tajara E.H. Gene amplification in carcinogenesis. Genet. Mol. Biol. 2006; 29: 1-7.
  11. Ruiz C. Identification and validation of novel amplification target genes in human breast cancer. Basel; 2006.
  12. Al-Kuraya K., Schraml P., Torhorst J., Tapia C., Zaharieva B., Novotny H. et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004; 64: 8534-40.
  13. Xu J., Chen Y., Olopade O.I. MYC and breast cancer. Genes & Cancer. 2010; 1: 629-40.
  14. Rummukainen J.K., Salminen T., Lundin J., Kytölä S., Joensuu H., Isola J.J. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod. Pathol. 2001; 14: 1030-5.
  15. Deming S.L., Nass S.J., Dickson R.B., Trock B.J. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br. J. Cancer. 2000; 83: 1688-95.
  16. Rodriguez-Pinilla S.M., Jones R.L., Lambros M.B., Arriola E., Savage K., James M. et al. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J. Clin. Pathol. 2007; 60: 1017-23.
  17. Singhi A.D., Cimino-Mathews A., Jenkins R.B., Lan F., Fink S.R., Nassar H. et al. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod. Pathol. 2012; 25: 378-87.
  18. Vaziri S.A.J., Tubbs R.R., Darlington G., Casey G. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. J. Clin. Pathol. Mol. Pathol. 2001; 54: 259-63.
  19. Jirström K., Stendahl M., Rydén L., Kronblad A., Bendahl P.O., Stål O., Landberg G. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 2005; 65: 8009-16.
  20. Arnold A., Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 2005; 23: 4215-24.
  21. Lundgren K., Holm K., Nordenskjöld B., Borg A., Landberg G. Gene products of chromosome 11q and their association withCCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res. 2008; 10: R1.
  22. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem. Cells. 1998; 16: 413-28.
  23. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25 (1): 118-45.
  24. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002; 20: 719-26.
  25. Lamy P.J., Fina F., Bascoul-Mollevi C., Laberenne A.C., Martin P.M., Ouafik L., Jacot W. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res. 2011; 13: 1-12.
  26. Burkhardt L., Grob T.J., Hermann I., Burandt E., Choschzick M., Jänicke F. et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 2010; 123: 757-65.
  27. Moelans C.B., de Weger R.A., Monsuur H.N., Vijzelaar R., van Diest P.J. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod. Pathol. 2010; 23: 1029-39.
  28. Bergamaschi A., Kim Y.H., Wang P., Sørlie T., Hernandez-Boussard T., Lonning P.E. et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes & Cancer. 2006; 45: 1033-40.
  29. Albertson D. G., Collins C., McCormick F., Gray J.W. Chromosome aberrations in solid tumors. Nat. Genet. 2003; 34: 369-76.
  30. Moelans C.B., de Weger R.A., Monsuur H.N., Maes A.H., van Diest P.J. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Anal. Cell. Pathol./Cell. Oncol. 2010; 33: 165-73.
  31. Schouten J.P., McElgunn C.J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucl. Acids Res. 2002; 30: e57.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.